Literature DB >> 15067533

[Irritable bowel syndrome].

W Häuser1, M Lempa.   

Abstract

The prevalence of irritable bowel syndrome (IBS) ranges in all countries of the world between 6 and 25%, in Germany between 15 and 22%. The divergent rates of prevalence are mainly due to different definitions of IBS in epidemiological studies. In Germany, 20-50% of persons with IBS symptoms seek medical help. IBS patients produce high direct and indirect costs. The following psychophysiological mechanisms of IBS are presumed to be empirically validated: visceral hypersensitivity, postinfectious sequelae, psychiatric disorders, and psychosocial stress. Tricyclic antidepressant agents and psychotherapy (hypnosis, cognitive behavioral therapy, and psychodynamic therapy) are effective for treatment of IBS forms dominated by pain. In one controlled study, the combination of pharmacological therapy and cognitive behavioral therapy was superior to pharmacological therapy alone.

Entities:  

Mesh:

Year:  2004        PMID: 15067533     DOI: 10.1007/s00482-003-0273-3

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  23 in total

Review 1.  [Consensus report: irritable bowel syndrome--definition, differential diagnosis, pathophysiology and therapeutic possibilities. Consensus of the German Society of Digestive and Metabolic Diseases].

Authors:  J Hotz; P Enck; H Goebell; I Heymann-Mönnikes; G Holtmann; P Layer
Journal:  Z Gastroenterol       Date:  1999-08       Impact factor: 2.000

2.  British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.

Authors:  J Jones; J Boorman; P Cann; A Forbes; J Gomborone; K Heaton; P Hungin; D Kumar; G Libby; R Spiller; N Read; D Silk; P Whorwell
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

Review 3.  Psychosocial aspects of the functional gastrointestinal disorders.

Authors:  D A Drossman; F H Creed; K W Olden; J Svedlund; B B Toner; W E Whitehead
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

4.  Phobic anxiety changes the function of brain-gut axis in irritable bowel syndrome.

Authors:  S Blomhoff; S Spetalen; M B Jacobsen; U F Malt
Journal:  Psychosom Med       Date:  2001 Nov-Dec       Impact factor: 4.312

Review 5.  Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

Authors:  William E Whitehead; Olafur Palsson; Kenneth R Jones
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

6.  Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness.

Authors:  Wendy M Gonsalkorale; Lesley A Houghton; Peter J Whorwell
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

7.  [A consecutive study of patients with irritable bowel disease in two tertiary referral centers].

Authors:  U Porsch; R Wanitschke; P Linhart; N Börner; M Bassler; P Galle; S O Hoffmann
Journal:  Psychother Psychosom Med Psychol       Date:  2001-07

8.  Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.

Authors:  F Creed; J Ratcliffe; L Fernandez; B Tomenson; S Palmer; C Rigby; E Guthrie; N Read; D Thompson
Journal:  Ann Intern Med       Date:  2001-05-01       Impact factor: 25.391

9.  The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome.

Authors:  I Heymann-Mönnikes; R Arnold; I Florin; C Herda; S Melfsen; H Mönnikes
Journal:  Am J Gastroenterol       Date:  2000-04       Impact factor: 10.864

10.  The economic impact of irritable bowel syndrome in a managed care setting.

Authors:  Rosalie P Patel; Antonio Petitta; Ronald Fogel; Edward Peterson; Barbara J Zarowitz
Journal:  J Clin Gastroenterol       Date:  2002-07       Impact factor: 3.062

View more
  1 in total

1.  Design and validation of a German version of the GSRS-IBS - an analysis of its psychometric quality and factorial structure.

Authors:  Sarah K Schäfer; Kathrin Julia Weidner; Jorge Hoppner; Nicolas Becker; Dana Friedrich; Caroline S Stokes; Frank Lammert; Volker Köllner
Journal:  BMC Gastroenterol       Date:  2017-12-04       Impact factor: 3.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.